These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 578665)

  • 1. Compensated low-dose 131I therapy of Graves' disease.
    Roudebush CP; Hoye KE; DeGroot LJ
    Ann Intern Med; 1977 Oct; 87(4):441-3. PubMed ID: 578665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
    Kaplowitz PB; Jiang J; Vaidyanathan P
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.
    Sridama V; McCormick M; Kaplan EL; Fauchet R; DeGroot LJ
    N Engl J Med; 1984 Aug; 311(7):426-32. PubMed ID: 6205272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome following standardized 185 MBq dose 131I therapy for Graves' disease.
    Watson AB; Brownlie BE; Frampton CM; Turner JG; Rogers TG
    Clin Endocrinol (Oxf); 1988 May; 28(5):487-96. PubMed ID: 3214941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
    Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
    J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
    Uy HL; Reasner CA; Samuels MH
    Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
    Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose 131I in treatment of Graves' disease.
    Lowdell CP; Dobbs HJ; Spathis GS; McCready VR; Cosgrove DO; Harmer CL
    J R Soc Med; 1985 Mar; 78(3):197-202. PubMed ID: 3838347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
    Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
    Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism.
    Marcocci C; Gianchecchi D; Masini I; Golia F; Ceccarelli C; Bracci E; Fenzi GF; Pinchera A
    J Endocrinol Invest; 1990 Jun; 13(6):513-20. PubMed ID: 2258580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early development of transient and permanent hypothyroidism following radioiodine therapy for hyperthyroid Graves' disease.
    Peden NR; Hart IR
    Can Med Assoc J; 1984 May; 130(9):1141-4. PubMed ID: 6546895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism.
    Ross DS; Daniels GH; De Stefano P; Maloof F; Ridgway EC
    J Clin Endocrinol Metab; 1983 Aug; 57(2):250-3. PubMed ID: 6688081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of RA 131I treatment protocols for Graves' disease.
    DeGroot LJ; Mangklabruks A; McCormick M
    J Endocrinol Invest; 1990 Feb; 13(2):111-8. PubMed ID: 2329258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dosage 131-I therapy of thyrotoxicosis (diffuse goiters). A five-year follow-up study.
    Cevallos JL; Hagen GA; Maloof F; Chapman EM
    N Engl J Med; 1974 Jan; 290(3):141-3. PubMed ID: 4859623
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 125I therapy in Graves' disease. Long-term results in 355 patients.
    McDougall IR; Greig WR
    Ann Intern Med; 1976 Dec; 85(6):720-3. PubMed ID: 1036667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
    Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
    Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient hypothyroidism after iodine-131 therapy for Grave's disease.
    Gómez N; Gómez JM; Orti A; Gavaldà L; Villabona C; Leyes P; Soler J
    J Nucl Med; 1995 Sep; 36(9):1539-42. PubMed ID: 7658207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine (131I) therapy of Graves' disease: use of the new high resolutional ultrasonic scanner for the determination of the accurate weight of the thyroid gland.
    Nagayama Y; Ashizawa K; Matsuo K; Inoue S; Harakawa S; Hirayu H; Yamashita S; Izumi M; Nagataki S
    Endocrinol Jpn; 1989 Jun; 36(3):359-65. PubMed ID: 2684619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.